NSE: GLENMARK · 30 September 2026 · Dated market coverage
- The stock is -4.37% at ₹2,334.70.
- Likely reason:Sector-wide pharma weakness and heavy volume-backed selling
- Approximate traded value is₹290.40 crore.
- It is -8.00% from its 52-week high and +30.24% from its 52-week low.
- The stock is being compared withNifty Pharmaalongside the Nifty 50.
Why Is Glenmark Pharmaceuticals Share Price Falling 4.37% Today?
Latest NSE EOD report: 2026-09-29. Today’s Volume: 1,243,830; 5-Day Avg. Volume: 952,671; 20-Day Avg. Volume: 526,878; Volume vs 20-Day Avg.: 2.36x; Delivery Quantity: 839,781; Delivery %: 65.75%; Number of Trades: 56,808.
Glenmark Pharmaceuticals declined sharply today, shedding 4.37% to close at ₹2,334.70. The stock opened lower at ₹2,398.20 and hovered near the day’s low of ₹2,334.70 throughout the session, reflecting persistent selling pressure. Trading activity spiked significantly, with volume clocking 2.36 times its 20-day average, signaling active participant liquidation.
The broader market sentiment remained weak, but Glenmark’s underperformance outpaced the benchmarks. While the Nifty index fell 0.42%, the Nifty Pharma sector index dropped 1.84% amid broader profit-taking in healthcare equities. Glenmark’s steeper correction aligns with its recent 5-day loss of 5.67%, suggesting broader sector weakness compounded by stock-specific unwinding.
While no single immediate company-specific catalyst was announced today, the company recently received an Establishment Inspection Report (EIR) from the U.S. FDA for its Goa facility with a Voluntary Action Indicated (VAI) classification, and expanded its respiratory footprint with the launch of Ryaltris in Brazil. However, these positive medium-term updates were overshadowed by immediate technical selling and sector-wide pressures.
medium confidence
- Stock fell 4.37% on high volume (2.36x 20-day average).
- Nifty Pharma sector declined 1.84%, reflecting broader industry profit-taking.
Research & Brokerage Views
Brokerage views are third-party opinions and are not WittyTrades recommendations.
WittyTrades Data Insight
Price Position:The stock is near the lower end of the day’s trading range.
Move From Open:-2.65%.
Intraday Range:2.94% of the previous close.
5-Day Performance:-5.67%; 20-Day Performance:-5.09%.
Latest Company Developments
What Should Traders and Investors Watch Next?
- Follow-through delivery and volume trends to check if institutional liquidation persists near support levels.
- Performance of the Nifty Pharma index and broader healthcare sector sentiment.
- Execution progress on recently launched products like Ryaltris in Brazil and US injectables.
- Upcoming corporate updates regarding the second quarter financial results window.
Catalyst note:No single same-day catalyst was reported; the decline reflects heavy volume-backed selling alongside broader pharma sector weakness.
Frequently Asked Questions
What is the likely reason for today’s move?
The downward move is best explained by a combination of broad sector headwinds in healthcare stocks and heavy volume-driven liquidation, with trading volumes surging to 2.36 times the 20-day average.
Is trading volume elevated?
Today’s volume is 1,243,830. The latest 20-day average available is 526,878, equivalent to about 2.36x of the recent average.
Before acting on this stock
Consult your own investment adviser before acting on any security. If you are interested in stock research or other available research categories, review theWittyTrades subscription plans and research segments.
Article by:WittyTrades Research Desk